Syntr Health Technologies, Inc., an Irvine, Calif.-based medical device company specializing in the processing of autologous adipose tissue, raised $2.2m in seed funding.
Backers included previous investors, angels and surgeons.
Led by Ahmed Zobi, Chief Executive Officer, Syntr Health Technologies aims to to assist physicians with a device that accelerates adipose tissue processing at the point of care.
The company, which is headquartered at University Lab Partners, a premier wet lab incubator in the heart of Orange County, intends to use the funds to build out sales for its patented, FDA-cleared SyntrFuge System™, a single-use disposable medical device that uses a patient’s own adipose tissue (also known as fat tissue) at the point of care.
The company announced FDA Clearance of their SyntrFuge System for harvesting, concentrating, and transferring of autologous adipose tissue, which is cleared for use in several surgical specialties when the transfer of harvested adipose tissue is desired, and released and listed with FDA its Class I SyntrFPU 360 device, a reusable lab centrifuge that facilitates expedited processing, as an accessory to the SyntrFuge System.
Syntr also added Dane Shackleford to its board of directors. Shackleford has held C-level positions with multiple medical device companies, most notably VP of Sales at KCI (an Acelity Company) and VP of Global Sales and Marketing at Spiracur, a Negative Wound Pressure Therapy company, which was acquired by Acelity in 2015. Other recent positions include Chief Commercial Officer for Dallas, Texas-based Stasis. Prior to that, he was CCO at Newport Beach, California-based Evoke Neuroscience; and before that, he was a regional VP at Phillips. Shackleford also sits on the Advisory Board at California Lutheran University.
FinSMEs
13/08/2021